This means understanding the dosing of peripherally restricted CB1R agonists to ensure they do not cross the blood brain barrier will also be of high importance for public safety since central CB1R activation enhances respiratory depression instead of mitigating it when administered alongside opioids (Wiese et al., 2021). Here, CNR1 is linked to Respiratory insufficiency due to muscle weakness.